Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Assessment of MRD in AML

Francesco Buccisano • 18 Sep 2020
SOHO Italy 2020
Leukemia

Francesco Buccisano, MD, University Tor Vergata, Rome, Italy, outlines the use of minimal residual disease (MRD) measurement in acute myeloid leukemia and outlines the use of MRD negativity in complete remission. Dr Buccisano also discusses assays to measure MRD, including next-generation sequencing and flow cytometry as well as the importance of improving the sensitivity of MRD assays. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Francesco Buccisano

1:39
An insight into MRD monitoring and MRD-driven treatment in AML
Francesco Buccisano • 24 Oct 2022
1:21
The importance of investigating AML disease biology & improving therapeutic options for patients
Francesco Buccisano • 24 Oct 2022
1:07
An insight into the pathogenesis of AML
Francesco Buccisano • 24 Oct 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals